Correction: Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis Study

Charytan DM, Foley R, McCullough PA, Rogers JD, Zimetbaum P, Herzog CA, Tumlin JA. Arrhythmia and sudden death in hemodialysis patients: protocol and baseline characteristics of the monitoring in dialysis study. Clin J Am Soc Nephrol 2016;11(4):721–734. doi:10.2215/CJN.09350915

The authors wish to note an error in the Base10.2215/CJN.09350915line Characteristics of the Study Population section and Table 4. The sentence “Use of cardiovascular medications was common, with 55%, 33%, and 48% of patients using β-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers or statins, respectively,” should instead read as “Use of cardiovascular medications was common, with 58%, 33%, and 48% of subjects using β-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers or lipid-lowering agents, respectively.” The corrected Table 4 appears below.

Table 4. - Baseline characteristics of enrolled patients

Characteristics	All Patients (n=66)	Patients in the United States (n=43)	Patients in India (n=23)	P Value
Mean age at implant±SD, yr (n/N)	56.3±12.2 (66/66)	55.8±11.6 (43/43)	57.2±13.5 (23/23)	0.66
Male sex	69.7 (46/66)	62.8 (27/43)	82.6 (19/23)	0.16
Race				<0.001
Asian	34.8 (23/66)	0.0 (0/43)	100.0 (23/23)
Black	53.0 (35/66)	81.4 (35/43)	0.0 (0/23)
Other	1.5 (1/66)	2.3 (1/43)	0.0 (0/23)
White	10.6 (7/66)	16.3 (7/43)	0.0 (0/23)
Hispanic ethnicity	0.0 (0/66)	0.0 (0/43)	0.0 (0/23)
Cause of ESRD
Diabetes	42.4 (28/66)	34.9 (15/43)	56.5 (13/23)	0.01
GN	7.6 (5/66)	7.0 (3/43)	8.7 (2/23)
Hypertension	37.9 (25/66)	51.2 (22/43)	13.0 (3/23)
Other	12.1 (8/66)	7.0 (3/43)	21.7 (5/23)
Median ESRD vintage (IQR), yr (n/N)	2.4 (1.2–5.3) (65/66)	3.5 (1.2–5.7) (42/43)	2.2 (1.1–3.0) (23/23)	<0.001
Previous kidney transplant	13.6 (9/66)	11.6 (5/43)	17.4 (4/23)	0.71
Previous peritoneal dialysis	10.6 (7/66)	14.0 (6/43)	4.3 (1/23)	0.41
Current vascular access
AV fistula	70.8 (46/65)	59.5 (25/42)	91.3 (21/23)	0.01
AV graft	24.6 (16/65)	35.7 (15/42)	4.3 (1/23)
Catheter	4.6 (3/65)	4.8 (2/42)	4.3 (1/23)
Diabetes				0.61
None	36.4 (24/66)	37.2 (16/43)	34.8 (8/23)
Type 1	4.5 (3/66)	7.0 (3/43)	0.0 (0/23)
Type 2	59.1 (39/66)	55.8 (24/43)	65.2 (15/23)
Mean diabetes duration±SD, yr (n/N)	17.9±12.8 (37/66)	21.0±13.6 (24/43)	12.1±9.0 (13/23)	0.04
Hyperlipidemia	60.6 (40/66)	74.4 (32/43)	34.8 (8/23)	0.003
Hypertension	84.8 (56/66)	97.7 (42/43)	60.9 (14/23)	<0.001
Ischemic heart disease	48.5 (32/66)	51.2 (22/43)	43.5 (10/23)	0.61
Congestive heart failure	25.8 (17/66)	39.5 (17/43)	0.0 (0/23)	<0.001
Coronary artery bypass surgery	13.6 (9/66)	11.6 (5/43)	17.4 (4/23)	0.71
History of arrhythmia	31.8 (21/66)	48.8 (21/43)	0.0 (0/23)	<0.001
Atrial fibrillation	10.6 (7/66)	16.3 (7/43)	0.0 (0/23)	0.09
Smoking				0.02
Current	7.6 (5/66)	11.6 (5/43)	0.0 (0/23)
Never	69.7 (46/66)	58.1 (25/43)	91.3 (21/23)
Past	22.7 (15/66)	30.2 (13/43)	8.7 (2/23)
Mean weight±SD, kg (n/N)	86.7±28.8 (66/66)	97.6±28.7 (43/43)	66.5±14.9 (23/23)	<0.001
Body mass index ≥40 kg/m2	9.1 (6/66)	14.0 (6/43)	0.0 (0/23)	0.08
Mean systolic BP±SD, mm Hg (n/N)	140.8±23.4 (66/66)	139.6±25.8 (43/43)	143.0±18.2 (23/23)	0.57
Mean diastolic BP±SD, mm Hg (n/N)	76.8±12.9 (66/66)	75.5±15.1 (43/43)	79.1±6.7 (23/23)	0.18
Medications
Nonaspirin anticoagulants or antiplatelet agents	56 (37/66)	63 (27/43)	43 (10/23)	0.19
β-blockers	58 (38/66)	60 (26/43)	52 (12/23)	0.61
Calcium channel blockers	58 (38/66)	53 (23/43)	65 (15/23)	0.44
ACEI or ARB	33 (22/66)	47 (20/43)	9 (2/23)	0.002
Lipid lowering	48 (32/66)	49 (21/43)	48 (11/23)	1.00
Aspirin	36 (24/66)	49 (21/43)	13 (3/23)	0.07

Unless otherwise noted, values are the number/number of patients (percentage). Categorical P value is based on a two-sided Fisher exact test. Continuous P value is based on an unpaired t test. IQR, interquartile range; AV, arteriovenous; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.